A Phase 2, Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma (FLC)
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2018
Price : $35 *
At a glance
- Drugs ENMD 2076 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors CASI Pharmaceuticals
- 04 Sep 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 07 Sep 2017 According to a CASI Pharmaceuticals media release, it is anticipated that the data from this study will be submitted to a medical conference for presentation in 2018.